3 unchanged sentences
(c) Insider Trading Arrangements and Policies.
−Removed: On August 7, 2025 , Pamela Cramer , the Company’s Chief Human Resources Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 29,566 shares of the Company’s common stock until November 1, 2026 .
−Removed: On August 8, 2025 , Jennifer Kayden Lee , the Company’s Executive Vice President, Head of North America , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 62,459 shares of the Company’s common stock as well as up to 100% of the shares of our common stock issued upon the settlement of outstanding restricted stock units, less the number of shares traded to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until June 1, 2026 .
−Removed: Other than as disclosed above, during the three months ended September 30, 2025, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
Incorporated by Reference
−Removed: Exhibit Description
+Added: Number Exhibit Description Form Date Number
3.1 Amended and Restated Certificate of Incorporation of Rhythm Pharmaceuticals, Inc.
1 unchanged sentence
dated June 25, 2025.
+Added: 8-K 06/26/2025 3.1
3.2 Amended and Restated Bylaws.
+Added: 8-K 12/18/2023 3.1
3.3 Certificate of Designations
+Added: 8-K 04/16/2024 3.1
3.4 Amended and Restated Certificate of Designations
+Added: 10-Q 05/07/2024 3.4
+Added: 4.1 F orm of Indenture
+Added: 2/26/2026 4.3
+Added: 10.1* Rhythm Pharmaceuticals, Inc.
+Added: Deferred Compensation P lan (Directors)
31.1* Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
2 unchanged sentences
32.2** Certification of the Principal Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
−Removed: Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
−Removed: Inline XBRL Taxonomy Extension Schema Document.
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: 101.INS* Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
+Added: 101.SCH* Inline XBRL Taxonomy Extension Schema Document.
+Added: 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
+Added: 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.
+Added: 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
3 unchanged sentences
RHYTHM PHARMACEUTICALS, INC.
−Removed: November 4, 2025
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 4, 2025
/s/ Hunter C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.